Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 22;15(9):e45787.
doi: 10.7759/cureus.45787. eCollection 2023 Sep.

Tenofovir-Induced Renal Dysfunction Among HIV-Infected Patients: A Systematic Review

Affiliations
Review

Tenofovir-Induced Renal Dysfunction Among HIV-Infected Patients: A Systematic Review

Yogamba M Shivakumar et al. Cureus. .

Abstract

Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug widely used as part of antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV-1) infection. Negative effects of tenofovir include impaired kidney function, especially with long-term use. In studies conducted among HIV-positive individuals, we found evidence of extensive kidney damage associated with TDF use. Despite the therapeutic importance of this consequence, its continued use in ART regimens was not contraindicated. The therapeutic and long-term effects of TDF are a major concern. However, in countries or settings where resources are limited and renal function monitoring cannot be ensured, screening methods to detect ART-related renal failure are still supported by data. Therefore, it is safe to re-evaluate the use of TDF-based ART. However, adherence to guidelines may be hampered by insufficient laboratory testing in low- and middle-income countries. More research is also needed among people under 18 years of age and pregnant and breastfeeding mothers.

Keywords: glomerular and tubular injury; hiv aids; kidney failure; tenofovir alafenamide (taf); tenofovir disoproxil fumarate (tdf).

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart.

References

    1. Tenofovir nephrotoxicity among Asians living with HIV: review of the literature. Nishijima T, Gatanaga H, Oka S. Glob Health Med. 2019;1:88–94. - PMC - PubMed
    1. Estimated glomerular filtration rate slopes on tenofovir alafenamide. Ibrahim F, Campbell L, Bailey AC, et al. HIV Med. 2020;21:607–612. - PubMed
    1. Renal toxicity of tenofovir: narrative review. Ali HH Aziz TA. Al-Rafidain J Med Sci. 2022;2:40–50.
    1. Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study. Hassan MO, Duarte R, Mabayoje VO, Dickens C, Lasisi AO, Naicker S. BMC Nephrol. 2020;21:436. - PMC - PubMed
    1. Long-term evaluation of changes in kidney function after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients living with HIV. Gilbert JM, Vest K, Kish TD. Pharmacy (Basel) 2022;10:164. - PMC - PubMed

LinkOut - more resources